De novo design of potent and selective interleukin mimetics
US-10844105-B2 · Nov 24, 2020 · US
IL-13
IL-13 · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K14/5437 |
| Official title | {IL-13} |
| Display label | IL-13 |
| Total patents | 130 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 9 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 8 |
| 2019 | 11 |
| 2020 | 16 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 12 |
| 2025 | 15 |
| 2026 | 6 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Epha3 and multi-valent targeting of tumors
US-2020347113-A1 · Nov 5, 2020 · US
De Novo Design of Potent and Selective Interleukin Mimetics
US-2020347109-A1 · Nov 5, 2020 · US
De Novo Design of Potent and Selective Interleukin Mimetics
US-2020339648-A1 · Oct 29, 2020 · US
Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
US-2020330534-A1 · Oct 22, 2020 · US
COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13R-alpha-2
US-2020318069-A1 · Oct 8, 2020 · US
De Novo Design of Potent and Selective Interleukin Mimetics
US-2020317744-A1 · Oct 8, 2020 · US
EPHA3 and multi-valent targeting of tumors
US-10752667-B2 · Aug 25, 2020 · US
De novo design of potent and selective interleukin mimetics
US-10703791-B2 · Jul 7, 2020 · US
Costimulatory chimeric antigen receptor T cells targeting IL13Rα2
US-10676717-B2 · Jun 9, 2020 · US
Multi-level specific targeting of cancer cells
US-2020095302-A1 · Mar 26, 2020 · US
De Novo Design of Potent and Selective Interleukin Mimetics
US-2020002398-A1 · Jan 2, 2020 · US
Multi-level specific targeting of cancer cells
US-10519210-B2 · Dec 31, 2019 · US
Fusion polypeptide in which anti-inflammatory polypeptide and ferritin monomer fragment are bound and pharmaceutical composition for preventing and treating inflammatory diseases, containing same as active ingredient
US-10513545-B2 · Dec 24, 2019 · US
Genetically modified non-human animals expressing human EPO
US-10463028-B2 · Nov 5, 2019 · US
Compositions and methods for treating fibrosis
US-2019183967-A1 · Jun 20, 2019 · US
Multi-level specific targeting of cancer cells
US-2019153057-A1 · May 23, 2019 · US
Therapeutic il-13 polypeptides
US-2019144518-A1 · May 16, 2019 · US
Cytokine-based fusion proteins for treatment of immune disorders
US-10273284-B2 · Apr 30, 2019 · US
Compositions and methods for treating fibrosis
US-10245298-B2 · Apr 2, 2019 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K14/5437?
- CPC C07K14/5437 is the Cooperative Patent Classification code for “IL-13.”
- How many patents are filed under CPC C07K14/5437 (IL-13)?
- Our database includes 130 publications tagged with this CPC code.
- Is patent activity under CPC C07K14/5437 growing?
- Publication counts under this code: 12 in 2024 vs 15 in 2025 (latest complete years).